

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LIFE HEALTHCARE GROUP LIMITED

蓮和醫療健康集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 928)

TERMINATION OF TRANSACTION

Reference is made to the announcements of the Company dated 30 March 2021 and 15 April 2021 (the “**Announcements**”) in relation to the proposed acquisition by the Company of an interest in a company engaging in the development of disinfection, sterilisation and cleaning projects. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those used in the Announcements.

The Board announces that as conditions (b) and (c) to the Agreement in respect of LHCS being satisfied with the results of its due diligence on the Target Group and the Operating Company, and the Vendor having provided LHCS with the audited financial statements of the post-reorganisation Target Group and the Operating Company have not been satisfied within the prescribed period of 90 days from the date of the Agreement, the parties to the Agreement have mutually agreed to terminate the Agreement on 28 June 2021. None of the parties is entitled to claim the other for any losses, damages or expenses as a result of the termination.

As no deposit or consideration in respect of the Acquisition has been paid, the Board does not consider the termination of the Agreement will have any material adverse effect on the operation of the Company. The Company will continue to explore other investment opportunities to expand the scope of the Group’s business and improve its overall performance.

By order of the Board
Life Healthcare Group Limited
Xu Xueping
Chairman and Executive Director

28 June 2021

As at the date of this announcement, the executive Directors are Mr. Xu Xueping and Mr. Man Wai Lun; the non-executive Director is Ms. Fu Xiaoji; and the independent non-executive Directors are Mr. Liu Xinghua, Mr. Cheng Chun Man and Ms. Zheng Xin.